Researchers claim blood test for Alzheimer’s disease is very accurate

New Blood Test Shows Promise for Early Alzheimer’s Detection

Researchers have developed a new blood test for Alzheimer’s disease that demonstrates high accuracy in identifying early symptoms. In their study, scientists focused on two proteins—amyloid beta 42/40 and p-tau217—and determined that the test is 95% effective in detecting patients with cognitive impairments linked to the disease.

This study, conducted in Florida, involved 509 patients at an outpatient memory clinic and was published in the journal Alzheimer’s and Dementia. Interestingly, the test has also achieved an 82% specificity rate, meaning it can effectively rule out individuals who do not have dementia.

Dr. Gregg Day, the lead on the study, emphasized that this new test is comparable to current methods, which tend to be more invasive. He mentioned that the next logical step is to broaden the testing to include individuals with early Alzheimer’s who might not exhibit cognitive symptoms yet.

Scientists have found these two proteins in blood plasma to be associated with amyloid plaque buildup. While amyloid is present in our brains normally, in cases of Alzheimer’s, it aggregates into harmful deposits that may damage brain cells.

Dr. Richard Oakley from the Alzheimer’s Society in the UK remarked on the findings, stating that they indicate the test’s high accuracy. He added, “Blood tests will be crucial in speeding up diagnosis and ensuring that more people receive the care and support they desperately need, much sooner.”

In the UK, initiatives like the Blood Biomarker Challenge underscore the collaborative effort to improve dementia diagnosis, receiving support from various organizations including the Alzheimer’s Society and Alzheimer’s Research UK.

The aim is to introduce blood tests for dementia diagnosis within the NHS by 2029. Dr. Julia Dudley, head of research at Alzheimer’s Research UK, expressed the urgency of advancing diagnostic practices and appreciated the international collaboration working towards this goal. She described studies, such as the Blood Biomarker Challenge, as vital steps toward making diagnosis quicker and more efficient, ultimately leading us closer to a potential cure.